Relay Therapeutics, Inc. (RLAY) News
Follow Relay Therapeutics, Inc. (RLAY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Relay Therapeutics to Announce Third-Quarter Results on November 4
Relay Therapeutics says it will announce third-quarter 2026 financial results and corporate highlights on November 4, 2026.
EQUITY | Oct 28, 2026, 08:16 PM UTC
L
RLAY zovegalisib progress targets breast cancer and vascular anomalies milestones
Updates cite robust progress in breast cancer and vascular anomalies programs, with zovegalisib showing strong efficacy and safety. Regulatory milestones and data readouts are expected by year-end, with a significant com
EQUITY | Sep 08, 2026, 07:27 PM UTC
M
RLAY’s zovegalisib reports efficacy and safety progress in trials
RLAY says zovegalisib has shown strong efficacy and safety data across its breast cancer and vascular anomalies programs, with regulatory updates and new trial launches expected soon as commercial preparations move ahead
EQUITY | Sep 08, 2026, 06:44 PM UTC
L
RLAY - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
RLAY - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
EQUITY | Sep 01, 2026, 08:46 PM UTC
L
RLAY - Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
RLAY - Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
EARNINGS | Jul 30, 2026, 08:07 PM UTC
L
Private Markets: Chai Discovery, Etched land major rounds
Chai Discovery and Etched secured hundreds of millions in new financing, pushing valuations into multibillion dollar territory and drawing comparisons to publicly traded leaders in their sectors. This week's private comp
EQUITY | Jul 23, 2026, 06:52 PM UTC
L
RLAY Initiated at Buy and $29 PT @ Canaccord
RLAY Initiated at Buy and $29 PT @ Canaccord
EQUITY | Jul 16, 2026, 12:42 PM UTC
L
RLAY Initiated Buy W/$29.00 PT at Canaccord
RLAY Initiated Buy W/$29.00 PT at Canaccord
EQUITY | Jul 16, 2026, 11:54 AM UTC
L
Relay Therapeutics Insider Sold Shares Worth $331,131, According to a Recent SEC Filing
() -- Thomas Catinazzo, Chief Financial Officer, on July 06, 2026, sold 17,717 shares in Relay Therapeutics (RLAY) for $331,131. Following the Form 4 filing with the SEC, Catinazzo has control over a total of 159,744 com
REGULATION | Jul 08, 2026, 09:13 PM UTC